MLNT - Melinta Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.56
-0.05 (-1.92%)
At close: 4:00PM EST

2.56 0.00 (0.00%)
After hours: 4:40PM EST

Stock chart is not supported by your current browser
Previous Close2.61
Open2.56
Bid2.41 x 1300
Ask2.78 x 1000
Day's Range2.46 - 2.62
52 Week Range2.25 - 18.20
Volume212,854
Avg. Volume454,358
Market Cap143.412M
Beta (3Y Monthly)2.05
PE Ratio (TTM)N/A
EPS (TTM)-3.78
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.60
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    New Research: Key Drivers of Growth for Fresh Del Monte Produce, Liquidity Services, B.O.S. Better Online Solutions, ePlus inc, Pluralsight, and Melinta Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Associated Press13 days ago

    Melinta Therapeutics, Inc.: 3Q Earnings Snapshot

    The New Haven, Connecticut-based company said it had a loss of 50 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates
    Zacks13 days ago

    Melinta Therapeutics, Inc. (MLNT) Reports Q3 Loss, Tops Revenue Estimates

    Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of 52.38% and 97.63%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire14 days ago

    Melinta Therapeutics Reports Third Quarter 2018 Financial Results

    New Product Launches Continue to Make Progress Setting the Stage for Growth in 2019Entered Commercial Agreement with Menarini Group to market Vabomere®, Orbactiv® and Minocin®.

  • GlobeNewswire20 days ago

    Melinta Therapeutics Announces Appointment of Bruce L. Downey to Board of Directors

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Bruce L. Downey to its Board of Directors. Mr. Downey is an accomplished executive with over 35 years of corporate management, legal and development experience. Currently, Mr. Downey serves as a partner at NewSpring, a venture capital firm, and is a member of the board of directors of Cardinal Health, Inc., serving on the audit committee, and Momenta Pharmaceuticals, as well as privately held companies.

  • GlobeNewswire23 days ago

    Melinta Therapeutics Announces Positive Top-Line Results in Phase III Trial of Baxdela® (delafloxacin) for Treatment of CABP

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced positive top-line results from its Phase III trial of Baxdela® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP). Baxdela was compared to moxifloxacin in this randomized global trial. Baxdela met all key primary and secondary endpoints in the trial, including the study’s primary U.S. Food and Drug Administration (FDA) endpoint showing Early Clinical Response (ECR) with improvement at 96 hours (± 24 hours) after the first dose in at least two of the following symptoms: chest pain, frequency or severity of cough, amount of productive sputum, and difficulty breathing.

  • GlobeNewswire26 days ago

    Melinta Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced it intends to release its third quarter 2018 financial results on November 7, 2018, prior to the opening of the U.S. financial markets. Melinta will host a conference call and live webcast on Wednesday, November 7, 2018 at 8:30 a.m. ET to discuss its financial results and provide a business update. On November 7, 2018 at 8:30 a.m. ET, the live call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers and using conference ID # 2096564.

  • GlobeNewswirelast month

    Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer

    Melinta Therapeutics, Inc., (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that its board of directors has appointed John H. Johnson as interim chief executive officer (CEO), effective immediately. Mr. Johnson, a director of Melinta, succeeds Dan Wechsler, who is stepping down from his role as president, CEO and director to pursue other opportunities. The Board and Mr. Wechsler mutually agreed that now is the right time to transition leadership of the Company.

  • GlobeNewswire2 months ago

    Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that findings from the first phase of the ongoing Clinical and Historic Registry and Orbactiv Medical Evaluation (CHROME) registry, a retrospective observational registry that seeks to characterize the use of Orbactiv® (oritavancin) for injection in real-world settings, have been published in the journal, Open Forum Infectious Diseases1. The findings showed safety and efficacy outcomes for Orbactiv in the real-world setting that were consistent with those seen in the previously published Orbactiv Phase 3 SOLO program.

  • GlobeNewswire2 months ago

    Melinta Therapeutics Publishes Complete Results from Phase III TANGO 2 Study of Vabomere™ (meropenem and vaborbactam)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that results from the Phase III TANGO 2 study of Vabomere™ (meropenem and vaborbactam) have been published in Infectious Diseases and Therapy1. Data from TANGO 2 showed that Vabomere was associated with increased clinical cure, and decreased mortality compared to “best available therapy” (BAT). Vabomere was approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of adult patients with complicated urinary tract infections (cUTI), including pyelonephritis, caused by designated susceptible Enterobacteriaceae.

  • GlobeNewswire2 months ago

    Melinta Therapeutics and Menarini Group Enter Commercial Agreement for Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 Countries

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to co-develop and commercialize Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin) and Minocin® (minocycline) for Injection in 68 countries in Europe, Asia-Pacific including China, South Korea, and Australia (Japan excluded), and the Commonwealth of Independent States (CIS) including Russia for a total consideration of up to $265 million. Under the terms of the agreement, Melinta will receive an upfront licensing fee, additional approval and sales-based milestone payments, and potential royalty payments based on a percentage of net sales of the three products.

  • GlobeNewswire2 months ago

    Melinta Therapeutics to Present at Upcoming Investor Conferences

    NEW HAVEN, Conn., Sept. 25, 2018 -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat.

  • GlobeNewswire2 months ago

    Melinta Therapeutics to Give New Presentations on Antibiotics Portfolio and Pipeline at IDWeek™ 2018

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that eight presentations and posters highlighting results from its antibiotics portfolio and pipeline will be presented at the Infectious Diseases Society of America IDWeek™ 2018 meeting, being held October 3 to 7, 2018 in San Francisco, CA. Poster and oral presentations for Melinta’s commercial and clinical-stage programs follow.

  • GlobeNewswire2 months ago

    Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vabomere™ (meropenem and vaborbactam) for approval as a treatment for adult patients with complicated intra-abdominal (cIAI) and urinary tract infections (cUTI), hospital-acquired pneumonia including ventilator associated pneumonia (HAP/VAP), bacteraemia that occurs in association with any of these infections, and infections due to aerobic Gram-negative organisms where treatment options are limited. The CHMP’s opinion will be reviewed by the European Commission (EC), which is expected to make a final decision regarding marketing authorization within 67 days of receiving the CHMP opinion.

  • Are Melinta Therapeutics Inc’s (NASDAQ:MLNT) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are Melinta Therapeutics Inc’s (NASDAQ:MLNT) Interest Costs Too High?

    Investors are always looking for growth in small-cap stocks like Melinta Therapeutics Inc (NASDAQ:MLNT), with a market cap of US$238.0m. However, an important fact which most ignore is: how financiallyRead More...

  • GlobeNewswire2 months ago

    Melinta Therapeutics Names Peter Milligan as Chief Financial Officer

    Melinta Therapeutics, Inc. (MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Peter Milligan as its new Chief Financial Officer, effective immediately. Milligan is an accomplished executive and established corporate leader who brings nearly 30 years of financial leadership experience, with extensive experience in managing all aspects of corporate and operational financial matters, including numerous capital market transactions. “We are excited to have Peter join our leadership team at this important moment for Melinta,” said Dan Wechsler, President and CEO of Melinta.

  • GlobeNewswire2 months ago

    Melinta Therapeutics to Host Meetings at the Morgan Stanley 16th Annual Global Healthcare Conference

    NEW HAVEN, Conn., Sept. 06, 2018-- Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced ...

  • GlobeNewswire3 months ago

    Melinta Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

    NEW HAVEN, Conn., Aug. 29, 2018-- Melinta Therapeutics, Inc., a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced ...

  • Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Lags Revenue Estimates
    Zacks3 months ago

    Melinta Therapeutics, Inc. (MLNT) Reports Q2 Loss, Lags Revenue Estimates

    Melinta Therapeutics, Inc. (MLNT) delivered earnings and revenue surprises of -32.69% and -0.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • ACCESSWIRE3 months ago

    Melinta Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Melinta Therapeutics, Inc. (NASDAQ: MLNT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...

  • PR Newswire6 months ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...